Statistiche di base
| LEI | 549300C775BNYF550E70 |
| CIK | 1590750 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Viridian Therapeutics, Inc.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| June 3, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio |
|
| May 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 27, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio |
|
| May 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2026 |
EX-1.2 Exhibit 1.2 $225,000,000 1.750% Convertible Senior Notes Due 2032 Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT May 6, 2026 JEFFERIES LLC LEERINK PARTNERS LLC GOLDMAN SACHS & CO. LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o GOLDMAN SAC |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| May 11, 2026 |
EX-4.1 Exhibit 4.1 VIRIDIAN THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of May 11, 2026 CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 |
|
| May 11, 2026 |
EX-4.2 Exhibit 4.2 VIRIDIAN THERAPEUTICS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of May 11, 2026 1.75% Convertible Senior Notes due 2032 CROSS REFERENCE TABLE* Trust Indenture Act Section Indenture Section 310(a)(1) N/A (a)(2) N/A (a)(3) N/A (a)(4) N/A (a)(5) N/A (b) N/A (c) N/A 311(a) N/A (b) N/A (c) N/A 312(a) N/A (b) N/A (c) N/A 3 |
|
| May 11, 2026 |
7,352,942 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 7,352,942 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT May 6, 2026 JEFFERIES LLC LEERINK PARTNERS LLC GOLDMAN SACHS & CO. LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 c/o GOLDMAN SACHS & CO. LLC 200 West |
|
| May 8, 2026 |
$225,000,000 1.75% Convertible Senior Notes due 2032 Viridian Therapeutics, Inc. 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-290056 PROSPECTUS SUPPLEMENT (To Prospectus dated September 5, 2025) $225,000,000 1.75% Convertible Senior Notes due 2032 Viridian Therapeutics, Inc. We are offering $225.0 million aggregate principal amount of our 1.75% convertible senior notes due 2032 (the “notes”). In addition, we have granted the underwriters an option to purchase, e |
|
| May 8, 2026 |
7,352,942 Shares of Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-290056 PROSPECTUS SUPPLEMENT (To Prospectus dated September 5, 2025) 7,352,942 Shares of Common Stock We are offering an aggregate of 7,352,942 shares of our common stock, par value $0.01 per share (“common stock”). Our common stock is traded on The Nasdaq Capital Market under the symbol “VRDN.” On May 6, 2026, the last reported sale pric |
|
| May 8, 2026 |
Calculation of Filing Fee Tables S-3 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| May 8, 2026 |
Calculation of Filing Fee Tables S-3 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| May 7, 2026 |
FWP Filed Pursuant to Rule 433 Registration No. 333-290056 Issuer Free Writing Prospectus, dated May 6, 2026 PRICING TERM SHEET MAY 6, 2026 Viridian Therapeutics, Inc. Offerings of $225.0 Million Aggregate Principal Amount of 1.75% Convertible Senior Notes due 2032 7,352,942 Shares of Common Stock The information in this pricing term sheet supplements (i) Viridian Therapeutics, Inc.’s (“Viridian”) |
|
| May 7, 2026 |
FWP Filed Pursuant to Rule 433 Registration No. 333-290056 Issuer Free Writing Prospectus, dated May 6, 2026 Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million WALTHAM, Mass., May 6, 2026 (BUSINESS WIRE) — Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnolog |
|
| May 6, 2026 |
$150,000,000 % Convertible Senior Notes due 2032 Viridian Therapeutics, Inc. 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 6, 2026 |
$100,000,000 Shares of Common Stock Shares of Series B Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| May 5, 2026 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress - PDUFA target action date of June 30, 2026 for veligrotug in thyroid eye disease (TED); organization is launch-ready - - Marketing Authorization Application (MAA) for veligrotug in TED submitted to the European Medicines Agency (EMA) in January 2026 and accepted for review in Feb |
|
| May 5, 2026 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-2 Clinical Trial in Chronic Thyroid Eye Disease - REVEAL-2 met its primary endpoint with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved 50% and 54% proptosis responder rates (PRR) at week 24, respectively, versus 15% placebo, both highly statisticall |
|
| May 5, 2026 |
Issuer Free Writing Prospectus Dated May 5, 2026 FWP Issuer Free Writing Prospectus Dated May 5, 2026 Relating to Preliminary Prospectus Supplement Dated May 5, 2026 Filed Pursuant to Rule 433 Registration Statement No. |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2026 |
EX-99.2 Exhibit 99.2 Corporate Presentation May 2026 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER |
|
| May 5, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| April 17, 2026 |
2025 Annual Report Framing the future of autoimmune diseases.Viridian is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for validated drug targets and d |
|
| April 17, 2026 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 17, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 30, 2026 |
EX-99.2 Corporate Presentation March 2026 Exhibit 99.2 This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would |
|
| March 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| March 30, 2026 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL-1 Clinical Trial in Active Thyroid Eye Disease - REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect - - Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24 - - Compl |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2026 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| February 26, 2026 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 10.39 [CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED.] SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”), dat |
|
| February 26, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.01 par value per share, to be issued pursuant to a Stock Option Inducement Award gran |
|
| February 26, 2026 |
Exhibit 10.43 Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential. PURCHASE AND SALE AGREEMENT by and between VIRIDIAN THERAPEUTICS, INC. AND DRI HEALTHCARE |
|
| February 26, 2026 |
As filed with the Securities and Exchange Commission on February 26, 2026 S-8 As filed with the Securities and Exchange Commission on February 26, 2026 Registration No. |
|
| February 26, 2026 |
Subsidiaries of the Registrant Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts |
|
| February 26, 2026 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - PDUFA target action date of June 30, 2026 for veligrotug for thyroid eye disease (TED); U.S. commercial preparations on track to support anticipated launch - - Marketing Authorization Application (MAA) for veligrotug for TED submitted to the European Medicines Age |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP |
|
| November 5, 2025 |
Exhibit 10.1 Certain portions of this exhibit (indicated by “[***]”) have been omitted in compliance with Regulation S-K Item 601(b)(10)(iv) as the Company determined the omitted information (i) is not material and (ii) is the type that the Company customarily and actually treats as private or confidential. COLLABORATION AND LICENSE AGREEMENT by and between Viridian Therapeutics, Inc. and Kissei P |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN |
|
| November 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| November 5, 2025 |
Exhibit 10.2 Final SIXTH AMENDMENT TO LEASE This SIXTH AMENDMENT TO LEASE (this "Amendment") is made as of the 8th day of September, 2025 (the “Effective Date”) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (“Landlord”), and VIRIDIAN THERAPEUTICS, INC |
|
| November 5, 2025 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Completed a comprehensive set of financing transactions in October 2025, securing access to up to $889 million of potential capital across equity, royalty, and credit - - Successful October submission of Biologics License Application (BLA) to the U.S. Food and Drug Administratio |
|
| October 23, 2025 |
11,425,000 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| October 23, 2025 |
11,425,000 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT EX-1.1 Exhibit 1.1 11,425,000 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT October 21, 2025 JEFFERIES LLC LEERINK PARTNERS LLC EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachuset |
|
| October 23, 2025 |
Calculation of Filing Fee Tables S-3 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| October 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| October 21, 2025 |
Shares of Common Stock Shares of Series B Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| October 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| September 5, 2025 |
As filed with the Securities and Exchange Commission on September 5, 2025. S-3ASR As filed with the Securities and Exchange Commission on September 5, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viridian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1187261 (State or other jurisdiction of incorporation or org |
|
| September 5, 2025 |
Calculation of Filing Fee Tables S-3 Viridian Therapeutics, Inc.\DE Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forw |
|
| August 6, 2025 |
Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to b |
|
| August 6, 2025 |
Viridian Therapeutics, Inc. 2025 Employee Stock Purchase Plan Adopted by the Board of Directors: April 23, 2025 Approved by the Stockholders: June 20, 2025 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a seri |
|
| August 6, 2025 |
As filed with the Securities and Exchange Commission on August 6, 2025 S-8 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| August 6, 2025 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results - Robust execution with multiple upcoming near-term milestones, including planned Biologics License Application (BLA) submission for veligrotug on track in 2H 2025 and expected U.S. commercial launch in 2026 - - Breakthrough Therapy Designation (BTD) for veligrotug announced in M |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA |
|
| July 30, 2025 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan - - Viridian to receive an upfront pay |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| June 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| June 24, 2025 |
Viridian Therapeutics, Inc. Amended and Restated 20 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 23, 2025 APPROVED BY THE STOCKHOLDERS: June 20, 2025 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive |
|
| May 20, 2025 |
Exhibit 99.1 Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with veligrotug in THRIVE who were proptosis responders at week 15 maintained their response at week 52 - - Veligrotug recently received Breakthrough Therapy Designation (BTD), supporting eligib |
|
| May 20, 2025 |
EX-99.2 THRIVE in Active TED 52-Week Follow-Up Update (May 20, 2025) Exhibit 99.2 This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “become,” “continue,” “could,” “design,” “estimate,” “expect,” “intend,” “may,” “might,” “on track,” “plan,” “potential,” “predict,” “project,” “should,” |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissio |
|
| May 6, 2025 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing VRDN-003 in active and chronic thyroid eye |
|
| May 6, 2025 |
Radhika Tripuraneni Employment Agreement, dated February 23, 2025. Exhibit 10.3 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of February 23, 2025 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 103A, Waltham, MA 02453 (the “Company”), and Radhika Tripuraneni, an individual residing at 12 Sunset Court, Menlo Park CA 94025 (“ |
|
| May 6, 2025 |
Exhibit 10.1 March 1, 2025 By Email Thomas Ciulla, MD 15977 Bridgewater Club Blvd Carmel, IN 46033 Dear Tom: This letter agreement (“Agreement”) confirms the terms of your separation without cause from Viridian Therapeutics, Inc. (“Viridian” or the “Company”).1 Unless you rescind your assent as set forth in Section 4(vii) below, this Agreement shall be effective, final and binding upon the expirat |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| April 25, 2025 |
DIFFERENTIATED PIPELINE: TED portfolio moving towards commercial and FeRn inhibitor portfolio first asset entered the clinic Thyroid Eye Disease (anti-IGF·1R) Portfolio FeRn-Targeting Autoimmune Portfolio Vellgrotug Intravenous VRDN-003 Subcutaneous VRDN-001 FcRn·target•ng Fe fragment VRDN-008 B•~P ""ftc extended half-ttfe FeRn mh•bitor DISCOVERY PRECLINICAL PH . |
|
| April 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte |
|
| April 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| April 7, 2025 |
Exhibit 99.1 Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Mr. Ajer was most recently Chief Commercial Officer at BioMarin - Waltham, Mass., April 7, 2025 — Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 5, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| March 4, 2025 |
Exhibit 1.1 EXECUTION VERSION OPEN MARKET SALE AGREEMENTSM March 3, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of t |
|
| March 4, 2025 |
Exhibit 107 Calculation of Filing Fee Tables 424 (b)(5) (Form Type) Viridian Therapeutics, Inc. |
|
| March 4, 2025 |
$300,000,000 Viridian Therapeutics, Inc. Common Stock 424B5 1 d126976d424b5.htm 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-267351 PROSPECTUS SUPPLEMENT (to Prospectus dated September 9, 2022) $300,000,000 Viridian Therapeutics, Inc. Common Stock We have entered into an Open Market Sale AgreementSM (the “Sale Agreement”), dated March 3, 2025, with Jefferies LLC (“Jefferies”), relating to shares of our common stock offered by this pros |
|
| March 3, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts |
|
| March 3, 2025 |
Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as material terms of our second restated certificate of incorporation (“certificate of incorporation”), fourth amended and restated bylaws (“bylaws”) and certain provisions of Delaware law. |
|
| March 3, 2025 |
Amendment to Seth Harmon Employment Agreement, dated February Exhibit 10.40 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Seth Harmon (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated April 24, 2023, as amended on September 28, 2023 (the “Agreement”). Capitalized terms used herein but not oth |
|
| March 3, 2025 |
As filed with the Securities and Exchange Commission on March 3, 2025 As filed with the Securities and Exchange Commission on March 3, 2025 Registration No. |
|
| March 3, 2025 |
Amendment to Stephen Mahoney Employment Agreement, dated February Exhibit 10.38 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Steve Mahoney (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated October 27, 2023 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall have the |
|
| March 3, 2025 |
Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to be |
|
| March 3, 2025 |
Exhibit 19 INSIDER TRADING POLICY (Approved February 12, 2025) I.INTRODUCTION Federal and state laws prohibit buying, selling or making other transfers of securities by persons who have material information that is not generally known or available to the public. These laws also prohibit persons with such Material Nonpublic Information from disclosing this information to others who trade. Trading w |
|
| March 3, 2025 |
Amendment to Thomas Beetham Employment Agreement, dated February Exhibit 10.39 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Thomas Beetham (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated October 27, 2023 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall have the |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP |
|
| March 3, 2025 |
Amendment to Jennifer Tousignant Employment Agreement, dated February Exhibit 10.41 VIRIDIAN THERAPEUTICS, INC. AMENDMENT TO EMPLOYMENT AGREEMENT Effective January 1, 2025 (the “Effective Date”), Viridian Therapeutics, Inc. (the “Company”) and Jennifer Tousignant (“Executive”) enter into this AMENDMENT (the “Amendment”) to the EMPLOYMENT AGREEMENT between them dated January 10, 2024 (the “Agreement”). Capitalized terms used herein but not otherwise defined shall hav |
|
| February 27, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2025 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved |
|
| February 14, 2025 |
EX-99.1 2 ex-99-02142025110232.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of Viridian Therapeutics, Inc. and further agree that t |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2024 |
Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Veligrotug met all primary and secondary endpoints with high statistical significance in THRIVE-2, achieving a week 15 proptosis responder rate (PRR) of 56% (placebo-adjusted PRR of 48%, p < 0.0001) - - THRIVE-2 is the first global pha |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| November 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm2427604d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this stateme |
|
| November 14, 2024 |
SC 13G/A 1 tm2428137d19sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Che |
|
| November 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d912234dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / Venrock Opportunities Fund, L.P. - SC 13G/A Passive Investment SC 13G/A 1 tm2428137d21sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Sta |
|
| November 12, 2024 |
Amendment to Lease by and between Registrant and Watch City Ventures MT, LLC dated as of Exhibit 10.1 FIFTH AMENDMENT TO LEASE This FIFTH AMENDMENT TO LEASE (this "Amendment") is made as of the 19th of September, 2024 (the “Effective Date”) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (“Landlord”), and VIRIDIAN THERAPEUTICS, INC., a Dela |
|
| November 12, 2024 |
Corporate Presentation November 2024 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “ |
|
| November 12, 2024 |
Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data - Reported positive topline phase 3 data for veligrotug from THRIVE in patients with active thyroid eye disease (TED); on track to report topline data from THRIVE-2 in chronic patients in December 2024 - - Initiated two global phase 3 clinical trials of subcutaneous VRDN-003, |
|
| November 12, 2024 |
Exhibit 10.2 [***] = Identified information has been excluded from this exhibit because it is both (i) information that the Company customarily and actually treats as private or confidential and (ii) is not material. AMENDED AND RESTATED LICENSE AGREEMENT This Amended and Restated License Agreement (this “Agreement”) is entered into and effective as of September 20, 2024 (the “A&R Effective Date”) |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN |
|
| November 12, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| October 18, 2024 |
VRDN / Viridian Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G/A 1 ViridianTherapeuticsInc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VIRIDIAN THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 92790C104 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the |
|
| September 17, 2024 |
VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A 1 tm2424267d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 |
|
| September 13, 2024 |
$225,000,000 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267351 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) $225,000,000 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock We are offering 10,666,600 shares of our common stock, par value $0.01 per share (“common stock”), and, in lieu of shares of our common stock to certain investors, 20,000 s |
|
| September 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Viridian Therapeutics, Inc. |
|
| September 12, 2024 |
Exhibit 1.1 Execution Version 10,666,600 Shares of Common Stock 20,000 Shares of Series B Preferred Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT September 11, 2024 JEFFERIES LLC GOLDMAN SACHS & CO. LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o GOLDMAN SACHS & CO. LLC 200 Wes |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com |
|
| September 10, 2024 |
Exhibit 99.1 Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Veligrotug (VRDN-001) achieved all primary and secondary endpoints in THRIVE, the largest phase 3 trial conducted to date of an anti-IGF-1R antibody in thyroid eye disease (TED), with a week 15 proptosis responder rate (PRR) of |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com |
|
| September 10, 2024 |
$150,000,000 Shares of Common Stock Shares of Series B Preferred Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-267351 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer |
|
| August 12, 2024 |
As filed with the Securities and Exchange Commission on August 12, 2024 S-8 As filed with the Securities and Exchange Commission on August 12, 2024 Registration No. |
|
| August 12, 2024 |
Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to |
|
| August 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| August 8, 2024 |
Exhibit 10.1 FOURTH AMENDMENT TO LEASE This FOURTH AMENDMENT TO LEASE (this "Amendment") is made as of the 8th day of April, 2024 (the “Effective Date”) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc., 125 High Street, Suite 531, Boston, Massachusetts 02110 (“Landlord”), and VIRIDIAN THERAPEUTICS, INC., a Del |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA |
|
| August 8, 2024 |
Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) remains on track for topline readout in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial in chronic TED topline readout expected year-end 2024; enrollment completed in July and exceeded |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 15, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| July 15, 2024 |
Exhibit 99.1 Corporate Presentation July 2024 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “m |
|
| June 20, 2024 |
EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 19, 2024 APPROVED BY THE STOCKHOLDERS: June 17, 2024 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity In |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| June 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 8, 2024 |
Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results - THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024 - - THRIVE-2 VRDN-001 global phase 3 clinical trial for patients with chronic TED remains on track |
|
| May 8, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER |
|
| April 26, 2024 |
20 2 3 Annual Report Framing the future of autoimmune diseases.DEAR SHAREHOLDER 2023 was an incredibly productive year for Viridian. We achieved several milestones in pursuit of our mission to develop potential best-in-class medicines for patients with serious and rare diseases, while evolving the organization toward Phase 3 readouts and potential commercialization. In our thyroid eye disease (TED |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| April 1, 2024 |
VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 West Conshohocken, PA 19428 (267 |
|
| February 28, 2024 |
Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value per share, to be |
|
| February 28, 2024 |
As filed with the Securities and Exchange Commission on February 28, 2024 As filed with the Securities and Exchange Commission on February 28, 2024 Registration No. |
|
| February 27, 2024 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant (as of February 27, 2024) Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts |
|
| February 27, 2024 |
Amendment to Seth Harmon Employment Agreement, dated September 28, 2023. Exhibit 10.11 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AMENDMENT (“Amendment”) is made as of September 28, 2023 by and between Viridian Therapeutics Inc., a Delaware corporation with a principal business address at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, with an address at 74 Chebacco Road, Hamilton, MA 01982 (“Executive”). WHEREAS, the Company and the Exe |
|
| February 27, 2024 |
Seth Harmon Employment Agreement, dated April 24, 2023. Exhibit 10.10 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of April 24, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Seth Harmon, an individual residing at 74 Chebacco Rd, Hamilton, MA 01982 (“Executive”). |
|
| February 27, 2024 |
Thomas Ciulla Employment Agreement, dated January 12, 2023. Exhibit 10.9 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of January 12, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Ciulla, an individual residing at 15977 Bridgewater Club Blvd, Carmel, IN 46033 ( |
|
| February 27, 2024 |
Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan. Exhibit 10.16 Viridian Therapeutics, INC. Amended and Restated 2016 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE Viridian Therapeutics, Inc. (the “Company”), pursuant to its Amended and Restated 2016 Equity Incentive Plan (the “Plan”), hereby grants to Optionholder an option to purchase the number of shares of the Company’s Common Stock set forth below. This option is subject to all of the term |
|
| February 27, 2024 |
Viridian Therapeutics, Inc. Incentive Compensation Clawback Policy. Exhibit 97.1 INCENTIVE COMPENSATION CLAWBACK POLICY Recoupment of Incentive-Based Compensation It is the policy of Viridian Therapeutics, Inc. (the “Company”) that, in the event the Company is required to prepare an accounting restatement of the Company’s financial statements due to material non-compliance with any financial reporting requirement under the federal securities laws (including any su |
|
| February 27, 2024 |
Form of Indemnity Agreement between the Registrant and each of its directors and executive officers. Exhibit 10.2 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (the “Agreement”) is made and entered into as of [●] between Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). RECITALS A. Highly competent persons have become more reluctant to serve corporations as directors or officers or in other capacities unless they are provided with adequate protection through |
|
| February 27, 2024 |
Exhibit 99.1 Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results - VRDN-001 Phase 3 THRIVE and THRIVE-2 topline clinical data readouts are expected for mid-year 2024 and year-end 2024, respectively - - Subcutaneous VRDN-003 pivotal program in thyroid eye disease expected to start mid-year 2024 pending regulatory authority alignment, as p |
|
| February 27, 2024 |
Lara Meisner Employment Agreement, dated May 11, 2023. Exhibit 10.6 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of May 11, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Lara Meisner, an individual residing at 11 Thornton Road, Needham, MA 02492 (“Executive”). ( |
|
| February 27, 2024 |
Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as material terms of our second restated certificate of incorporation (“certificate of incorporation”), fourth amended and restated bylaws (“bylaws”) and certain provisions of Delaware law. |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP |
|
| February 27, 2024 |
Jennifer Tousignant Employment Agreement, dated January 10, 2024. Exhibit 10.12 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), dated as of January 10, 2024 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Jennifer Tousignant, an individual residing at 29 Wheelock Road, Sutton, MA 01590 (“Ex |
|
| February 27, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2024 |
Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan. Exhibit 10.17 VIRIDIAN THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2016 AMENDED AND RESTATED EQUITY INCENTIVE PLAN) Viridian Therapeutics, Inc. (the “Company”), pursuant to its 2016 Amended and Restated Equity Incentive Plan (the “Plan”), hereby awards to Participant the number of restricted stock units set forth below (“Award”). This Award is subject to all of the terms and conditions |
|
| February 27, 2024 |
2016 Amended and Restated Employee Stock Purchase Plan. Exhibit 10.18 Viridian Therapeutics, Inc. 2016 Amended and Restated Employee Stock Purchase Plan Adopted by the Board of Directors: November 30, 2016 Approved by the Stockholders: February 10, 2017 Amended and Restated by the Board of Directors: March 30, 2023 1.GENERAL; PURPOSE. (a)The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may |
|
| February 14, 2024 |
SC 13G/A 1 sc13ga307422vrdn02142024.htm AMENDMENT NO. 3 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 p |
|
| February 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm245955d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this statement |
|
| February 14, 2024 |
VRDN / Viridian Therapeutics, Inc. / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d28sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check |
|
| February 13, 2024 |
VRDN / Viridian Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02227-viridiantherapeutics.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Viridian Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 92790C104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| January 29, 2024 |
VRDN / Viridian Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) January 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| January 29, 2024 |
EX-99.1 2 d744744dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: January 29, 20 |
|
| January 29, 2024 |
VRDN / Viridian Therapeutics, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us92790c1045012924.txt us92790c1045012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Viridian Therapeutics, Inc.\DE - (Name of Issuer) Common Stock - (Title of Class of Securities) 92790C104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the app |
|
| January 24, 2024 |
VRDN / Viridian Therapeutics, Inc. / STATE STREET CORP Passive Investment SC 13G 1 ViridianTheraInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING VIRIDIAN THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 92790C104 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE P |
|
| January 24, 2024 |
VRDN / Viridian Therapeutics, Inc. / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A 1 d75782dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 Wes |
|
| January 19, 2024 |
7,142,858 Shares of Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267351 PROSPECTUS SUPPLEMENT (To Prospectus dated September 9, 2022) 7,142,858 Shares of Common Stock We are offering 7,142,858 shares of our common stock, par value $0.01 per share (“common stock”). Our common stock is traded on The Nasdaq Capital Market under the symbol “VRDN.” On January 17, 2024, the last reported sa |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| January 19, 2024 |
Exhibit 1.1 Execution Version 7,142,858 Shares of Common Stock Viridian Therapeutics, Inc. UNDERWRITING AGREEMENT January 17, 2024 JEFFERIES LLC LEERINK PARTNERS LLC As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o LEERINK PARTNERS LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 Ladies and Gentlemen: Introductory. Viridian |
|
| January 19, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Viridian Therapeutics, Inc. |
|
| January 17, 2024 |
Shares of Common Stock Shares of Series B Preferred Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. |
|
| January 10, 2024 |
VRDN / Viridian Therapeutics, Inc. / FMR LLC Passive Investment SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 VIRIDIAN THERAPEUTICS INC COMMON STOCK Cusip #92790C104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #92790C104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,624,631 Item 6: 0 Item 7: 7,625,542 Item 8: 0 Ite |
|
| January 8, 2024 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference - VRDN-001 topline clinical results for THRIVE and THRIVE-2 on track for mid-2024 and year-end 2024 in patients with active and chronic thyroid eye disease (TED), respectively - - Subcutaneous VRDN-003 pivotal study in TED anticipated to start in mid-2024, pending alignment with |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| December 18, 2023 |
Fourth Amended and Restated Bylaws of the Registrant, effective as of December 15, 2023. EX-3.1 Exhibit 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both wi |
|
| December 18, 2023 |
EX-99.2 Exhibit 99.2 Subcutaneous IGF-1R Program Selection December 18, 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate, |
|
| December 18, 2023 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease - VRDN-003 clinical data exceeded expectations with extended half-life of 40-50 days, 4-5x longer than VRDN-001, supporting a potential best-in-c |
|
| December 8, 2023 |
VRDN / Viridian Therapeutics Inc / Venrock Opportunities Fund, L.P. - SC 13G Passive Investment SC 13G 1 tm2332269d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C 104 (CUSIP Number) November 1, 2023 (Date of Event Which Requires Filing of this Statement) Che |
|
| November 30, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Viridian Therapeutics, Inc. |
|
| November 30, 2023 |
EX-10.1 Exhibit 10.1 FORM OF SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of , 2023, by and among VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purch |
|
| November 30, 2023 |
As filed with the Securities and Exchange Commission on November 30, 2023 S-3ASR As filed with the Securities and Exchange Commission on November 30, 2023 Registration No. |
|
| November 30, 2023 |
EX-4.2 Exhibit 4.2 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of , 2023, by and among Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Secur |
|
| November 13, 2023 |
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. |
|
| November 13, 2023 |
Exhibit 3.2 THIRD AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within and |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| November 13, 2023 |
Thomas Beetham Employment Agreement, dated October 27, 2023. VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Thomas Beetham (“Executive”). (Executive and the Company collectively the “Parties” and each of the P |
|
| November 13, 2023 |
Exhibit 99.1 Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 - - Timing for the selection of lead subcutaneous TED program is on track for the e |
|
| November 13, 2023 |
Stephen Mahoney Employment Agreement, dated October 27, 2023 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of October 27, 2023 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Steve Mahoney (“Executive”). (Executive and the Company collectively the “Parties” and each of the Pa |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN |
|
| November 3, 2023 |
VRDN / Viridian Therapeutics Inc / Fairmount Funds Management LLC - SC 13D/A Activist Investment SC 13D/A 1 d563332dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C 104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive, Suite 400 We |
|
| November 2, 2023 |
Third Amended and Restated Bylaws of the Company, effective as of November 1, 2023. Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF VIRIDIAN THERAPEUTICS, INC. ARTICLE 1 OFFICES Section 1.01. Registered Office. The registered office of Viridian Therapeutics, Inc. (hereinafter, the “Corporation”) shall be in the City of Wilmington, County of New Castle, State of Delaware 19810. Section 1.02. Other Offices. The Corporation may also have offices at such other places both within an |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| October 30, 2023 |
Exhibit 99.1 Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing – Stephen Mahoney appointed President and Chief Executive Officer – – Potential best-in-class subcutaneous and intravenous thyroid eye disease (TED) programs targeting insulin-like growth factor 1 receptor (IGF-1R) remain on |
|
| October 30, 2023 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| October 30, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 30, 2023, by and among VIRIDIAN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and each purchaser identified on Annex A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS A. The Company and each Purchaser i |
|
| October 30, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is dated as of October 30, 2023, by and among Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers signatory hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Com |
|
| September 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Comm |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THERA |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 S-8 As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| August 8, 2023 |
EX-FILING FEES Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe |
|
| July 24, 2023 |
As filed with the Securities and Exchange Commission on July 24, 2023 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on July 24, 2023 Registration No. |
|
| July 24, 2023 |
Exhibit 107 EX-FILING FEES Calculation of Filing Fee Tables FORM S-3 (Form Type) Viridian Therapeutics, Inc. |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| July 17, 2023 |
EX-99.1 Exhibit 99.1 ® Corporate Overview July 2023 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, anticipate, believe, continue, could, estimate, expect, intend, may, might, plan, |
|
| July 10, 2023 |
EX-99.2 VRDN-001 Phase 1/2 results in patients with chronic TED July 2023 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," |
|
| July 10, 2023 |
EX-99.1 Exhibit 99.1 Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED ame |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| June 16, 2023 |
Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. AMENDED & RESTATED 2016 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: April 10, 2023 APPROVED BY THE STOCKHOLDERS: June 14, 2023 1. GENERAL. (a) Continuation of Existing Plan; Successor to and Continuation of Prior Plans. The Plan is intended to serve as a continuation of the Viridian Therapeutics, Inc. Amended and Restated 2016 Equity In |
|
| June 14, 2023 |
VRDN / Viridian Therapeutics Inc / Atlas Venture Fund VII L P - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (Amendment No. 1)* VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 92790C104 (CUSIP Number) Accomplice Attention: Frank Cast |
|
| May 11, 2023 |
VRDN / Viridian Therapeutics Inc / Paradigm Biocapital Advisors LP - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) May 1, 2023 (Date of Event Which Requires Filing of this statement) Check the appropriate box to designate the rul |
|
| May 11, 2023 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN THER |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update - Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection of lead subcutaneous (SC) program in TED planned for year-end 2023 - - Company adds multiple senior executives to its leadership te |
|
| May 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 28, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 28, 2023 |
Engineering medicines to improve patient care. 2022 Annual ReportABOUT VIRIDIAN THERAPEUTICS Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously val |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commiss |
|
| March 10, 2023 |
Form of Inducement Restricted Stock Unit Agreement. EX-99.4 Exhibit 99.4 VIRIDIAN THERAPEUTICS, INC. RESTRICTED STOCK UNIT GRANT NOTICE (2016 AMENDED AND RESTATED EQUITY INCENTIVE PLAN) Viridian Therapeutics, Inc. (the “Company”), pursuant to its 2016 Amended and Restated Equity Incentive Plan (the “Plan”), hereby awards to Participant the number of restricted stock units set forth below (“Award”). This Award is subject to all of the terms and cond |
|
| March 10, 2023 |
EX-FILING FEES Exhibit 107.1 Form S-8 (Form Type) VIRIDIAN THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.01 par value pe |
|
| March 10, 2023 |
Power of Attorney (included on signature page hereto). S-8 As filed with the Securities and Exchange Commission on March 10, 2023 Registration No. |
|
| March 9, 2023 |
Subsidiaries of the Registrant. Exhibit 21.1 Subsidiaries of the Registrant (as of March 9, 2023) Name of Subsidiary Jurisdiction of Incorporation Viridian Therapeutics Europe Limited England and Wales Viridian Therapeutics S.á.r.l. Luxembourg Viridian Securities Corporation Massachusetts |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36483 VIRIDIAN THERAP |
|
| March 9, 2023 |
Exhibit 4.5 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 General The following is a summary of the material terms of our capital stock, as well as other material terms of our second restated certificate of incorporation (“certificate of incorporation”) and second amended and restated bylaws (“bylaws”) and certain provisions of Dela |
|
| March 8, 2023 |
EX-99.1 Exhibit 99.1 Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates - Positive data reported from ongoing Phase 1/2 trial evaluating low-dose VRDN-001 in patients with thyroid eye disease (TED) - - First patient enrolled in ‘THRIVE’ Phase 3 trial in patients with active TED, with results expected in mid-2024 - - Initial results from |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commissi |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Numbe |
|
| February 14, 2023 |
VRDN / Viridian Therapeutics Inc / TCG Crossover GP I, LLC - AMENDMENT NO. 3 Passive Investment SC 13G/A 1 viri213231sc13ga3.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) |
|
| February 14, 2023 |
VRDN / Viridian Therapeutics Inc / Paradigm Biocapital Advisors LP - SC 13G/A Passive Investment SC 13G/A 1 tm236410d5sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this statement) |
|
| February 14, 2023 |
VRDN / Viridian Therapeutics Inc / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2023 |
VRDN / Viridian Therapeutics Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
SC 13G/A 1 tm236584d4sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 92790C104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 9, 2023 |
VRDN / Viridian Therapeutics Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv02197-viridiantherapeutics.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Viridian Therapeutics Inc. Title of Class of Securities: Common Stock CUSIP Number: 92790C104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule p |
|
| February 6, 2023 |
EX-99.1 Exhibit 99.1 NEWS RELEASE Viridian Appoints Scott Myers as President and Chief Executive Officer - Transition highlights Viridian’s progression towards becoming a fully-integrated biopharmaceutical company – Waltham, Mass. — February 6, 2023 — Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commi |
|
| February 6, 2023 |
Jonathan Violin General Release and Separation and Consulting Agreement, dated February 6, 2023 EX-10.2 Exhibit 10.2 221 Crescent Street Suite 401 Waltham, MA 02453 617-272-4600 Viridiantherapeutics.com GENERAL RELEASE AND SEPARATION AND CONSULTING AGREEMENT This General Release and Separation and Consulting Agreement (this “Agreement”) is made this 6th day of February 2023 (the “Separation Date”) by and between Viridian Therapeutics, a Delaware corporation (the “Company”), and Jonathan Viol |
|
| February 6, 2023 |
Scott Myers Employment Agreement, dated December 29, 2022 EX-10.1 Exhibit 10.1 VIRIDIAN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”), dated as of December 29, 2022 (the “Effective Date”), is by and between Viridian Therapeutics, Inc., a Delaware corporation, located at 221 Crescent Street, Suite 401, Waltham, MA 02453 (the “Company”), and Scott Myers, an individual residing at 160 Waverly Way, Kirkland, WA 98033 (“E |
|
| February 3, 2023 |
VRDN / Viridian Therapeutics Inc / BlackRock Inc. Passive Investment us92790c1045020323.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) MIRAGEN THERAPEUTICS, INC. - (Name of Issuer) Common Stock - (Title of Class of Securities) 92790C104 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 26, 2023 |
VRDN / Viridian Therapeutics Inc / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) VIRIDIAN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 92790C104 (CUSIP Number) DECEMBER 31, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate t |
|
| January 9, 2023 |
VRDN-001 3 mg/kg results in patients with TED January 2023 Exhibit 99.2 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "ex |
|
| January 9, 2023 |
EX-99.1 2 d427009dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) - Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg results – - Among 3 mg/kg VRDN-001 treated patients, 6 |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2023 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36483 VIRIDIAN |
|
| November 14, 2022 |
Final THIRD AMENDMENT TO LEASE This THIRD AMENDMENT TO LEASE (this "Amendment") is made as of the 29th day of July, 2022 (the ?Effective Date?) by and between WATCH CITY VENTURES MT LLC, a Massachusetts limited liability company, having an address at c/o Berkeley Investments, Inc. |
|
| September 9, 2022 |
Exhibit 4.3 VIRIDIAN THERAPEUTICS, INC. Debt Securities Indenture Dated as of , 202 [ ], as Trustee CROSS-REFERENCE TABLE This Cross-Reference Table is not a part of the Indenture TIA Section Indenture Section 310(a)(1) 7.10 (a)(2) 7.10 (a)(3) N.A. (a)(4) N.A. (b) 7.08; 7.10; 12.02 311(a) 7.11 (b) 7.11 (c) N.A. 312(a) 2.05 (b) 12.03 (c) 12.03 313(a) 7.06 (b)(1) N.A. (b)(2) 7.06 (c) 12.02 (d) 7.06 |
|
| September 9, 2022 |
, dated as of September 9, 2022 by and between the Registrant and Jefferies LLC. EX-1.2 2 d347132dex12.htm EX-1.2 Exhibit 1.2 OPEN MARKET SALE AGREEMENTSM September 9, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Viridian Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “A |
|
| September 9, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 Registration Statement under the Securities Act of 1933 (Form Type) Viridian Therapeutics, Inc. |
|
| September 9, 2022 |
S-3ASR 1 d347132ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 9, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Viridian Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 ( |
|
| August 19, 2022 |
VRDN / Viridian Therapeutics Inc / Fairmount Funds Management LLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Viridian Therapeutics, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 92790C104 (CUSIP Number) Ms. Erin O’Connor Fairmount Funds Management LLC 200 Barr Harbor Drive Suite 400 West Conshohocken, PA 19428 (267) 262-5300 |
|
| August 19, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2022 VIRIDIAN THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36483 47-1187261 (State or other jurisdiction of incorporation) (Commis |
